SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-16-511157
Filing Date
2016-03-21
Accepted
2016-03-21 09:14:30
Documents
4
Period of Report
2016-03-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d164248d8k.htm 8-K 27249
2 EX-99.1 d164248dex991.htm EX-99.1 25849
3 GRAPHIC g1642481.jpg GRAPHIC 8699
4 GRAPHIC g1642482.jpg GRAPHIC 6259
  Complete submission text file 0001193125-16-511157.txt   75357
Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8
Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792
Valeant Pharmaceuticals International, Inc. (Filer) CIK: 0000885590 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14956 | Film No.: 161517685
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences